Report highlights contributions of genomics to advances in public health and overall health of our planet
Published 04-07-22
Submitted by Illumina
Originally published on Illumina News Center
SAN DIEGO, April 7, 2022 /CSRwire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today released its annual Corporate Social Responsibility (CSR) Report, highlighting the company's 2021 environmental, social, and governance (ESG) program and commitment to human health. The report details Illumina's role as a champion for patients, communities, people, and the planet.
"Over the last year, we saw countless examples of resilience, perseverance, and progress as we continue to respond to the pandemic, push for greater access to and equity in genomics, and protect our planet," said Francis de Souza, Chief Executive Officer. "Through our advanced technology, we empower researchers and clinicians to find solutions for the world's most pressing challenges. As we look forward, we are focused on continuing to positively impact the world by unlocking the power of the genome to shape a more sustainable, more equitable, and healthier future for all."
Illumina's ESG efforts outlined in the Report include the following focus areas:
In 2021, the company took significant steps to advance each of these areas, including:
Read the full report on Illumina's CSR website.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Investors:
Salli Schwartz
+1.858.291.6421
ir@illumina.com
Media:
Adi Raval
202.629.8172
ILMN-PR@illumina.com
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
More from Illumina